AI Pathology Model Validated Across Triple-Negative and HER2+ Breast Cancer Subtypes

kjgeras · x · 2026-07-06

Unlike existing genomic tests primarily designed for HR+/HER2-, this AI test performs effectively across all major breast cancer subtypes, including triple-negative (C-index 0.71) and HER2+ (C-index 0.67). Currently, there are no guideline-supported prognostic or predictive tests for these two subtypes.

Related event: Multimodal AI Pathology Test Outperforms Gold Standard in Breast Cancer Recurrence Prediction(11 posts)→

Original post →

More from Research

Research channel →